Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of BIO 300 Oral Suspension in Discharged COVID-19 Patients

NCT04482595 is registered in ClinicalTrials.gov with Humanetics Corporation as lead sponsor.

NCT NCT04482595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04482595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of BIO 300 Oral Suspension in Discharged COVID-19 Patients
Lead sponsor
Humanetics Corporation
Phase
Phase 2
Overall status
Unknown status
Start date
November 11, 2020
Completion date
April 30, 2025
Enrollment
50 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, long covid, post-acute respiratory complications of covid-19, pulmonary fibrosis